NMTC
insider transactionsNEUROONE MEDICAL TECHNOLOGIES Corp — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+970.0K
1.0M buy · 30.0K sell
Net value · 365d
$647.3K
$670.4K in · $23.1K out
Sentiment · 365d
Net buying
97% buying · 3% selling
Open-market trades · 365d
6
1.0M buy · 30.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
26.0K sh
Own New
-
Grant·A
Director
$0
41.9K sh
Own +540%
-
Grant·A
Director
$0
26.0K sh
Own New
-
Grant·A
Director
$0
41.9K sh
Own +37%
-
Grant·A
Director
$0
26.0K sh
Own New
-
Grant·A
Director
$0
41.9K sh
Own +46%
-
Other·F
David A Rosa KEY
CEO and President
$1.9K
2.5K sh · $0.78
Own -0%
-
Other·F
Chief Technology Officer
$704
906 sh · $0.78
Own -1%
-
Other·F
Business Development Director
$197
253 sh · $0.78
Own -0%
-
Sell·S
Business Development Director
$11.4K
15.4K sh · $0.74
Own -7%
-
Sell·S
Business Development Director
$80
100 sh · $0.80
Own -0%
-
Sell·S
Business Development Director
$654
817 sh · $0.80
Own -0%
-
Sell·S
Business Development Director
$1.7K
2.1K sh · $0.80
Own -1%
-
Sell·S
Business Development Director
$9.3K
11.6K sh · $0.80
Own -5%
-
Grant·A
Chief Business Officer
$0
500.0K sh
Own New
-
Buy·P
Chief Business Officer
$670.4K
1.0M sh · $0.67
Own New
-
Other·F
David A Rosa KEY
CEO and President
$48.5K
71.3K sh · $0.68
Own -6%
-
Other·F
Chief Technology Officer
$5.0K
7.4K sh · $0.68
Own -5%
-
Other·F
Business Development Director
$1.2K
1.8K sh · $0.68
Own -1%
-
Other·F
David A Rosa KEY
CEO and President
$1.9K
2.5K sh · $0.76
Own -0%
-
Other·F
Chief Technology Officer
$687
906 sh · $0.76
Own -1%
-
Other·F
Business Development Director
$192
253 sh · $0.76
Own -0%
-
Grant·A
Director
$0
4.8K sh
Own New
-
Grant·A
Director
$0
7.8K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 3, 2026 | Jason Richard Mills | Grant A | 26.0K | $0 |
| Apr 3, 2026 | Jason Richard Mills | Grant A | 41.9K | $0 |
| Apr 3, 2026 | Jeffrey S Mathiesen | Grant A | 26.0K | $0 |
| Apr 3, 2026 | Jeffrey S Mathiesen | Grant A | 41.9K | $0 |
| Apr 3, 2026 | Edward Andrle | Grant A | 26.0K | $0 |
| Apr 3, 2026 | Edward Andrle | Grant A | 41.9K | $0 |
| Mar 31, 2026 | David A Rosa KEY | Other F | 2.5K | $1.9K |
| Mar 31, 2026 | Steve Mertens | Other F | 906 | $704 |
| Mar 31, 2026 | Mark Christianson | Other F | 253 | $197 |
| Mar 30, 2026 | Mark Christianson | Sell S | 15.4K | $11.4K |
| Mar 13, 2026 | Mark Christianson | Sell S | 100 | $80 |
| Mar 12, 2026 | Mark Christianson | Sell S | 817 | $654 |
| Mar 11, 2026 | Mark Christianson | Sell S | 2.1K | $1.7K |
| Mar 10, 2026 | Mark Christianson | Sell S | 11.6K | $9.3K |
| Mar 1, 2026 | David J. Wambeke | Grant A | 500.0K | $0 |
| Mar 1, 2026 | David J. Wambeke | Buy P | 1.0M | $670.4K |
| Feb 18, 2026 | David A Rosa KEY | Other F | 71.3K | $48.5K |
| Feb 18, 2026 | Steve Mertens | Other F | 7.4K | $5.0K |
| Feb 18, 2026 | Mark Christianson | Other F | 1.8K | $1.2K |
| Dec 31, 2025 | David A Rosa KEY | Other F | 2.5K | $1.9K |
| Dec 31, 2025 | Steve Mertens | Other F | 906 | $687 |
| Dec 31, 2025 | Mark Christianson | Other F | 253 | $192 |
| Dec 18, 2025 | Jason Richard Mills | Grant A | 4.8K | $0 |
| Dec 18, 2025 | Jason Richard Mills | Grant A | 7.8K | $0 |
About NMTC insider trading
This page tracks insider transactions for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.